Tetrazanbigen

TargetMol
Product Code: TAR-T34829
Supplier: TargetMol
CodeSizePrice
TAR-T34829-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34829-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Tetrazanbigen is an inducer of S phase arrest and apoptosis in hepatocellular carcinoma QGY-7701.
CAS:
T34829
Molecular Weight:
288.35
Purity:
0.98
SMILES:
C1(N=C2NCC34)=CC=CC=C1N=C2N4CCC5=C3C=CC=C5

References

Yuan YH, Yang XL, Li W, Zheng XH, Gu R, Yu Y. [Subcellular proteomic analysis of Tetrazanbigen on human hepatocellular carcinoma cell line QGY-7701]. Zhonghua Gan Zang Bing Za Zhi. 2011 Dec;19(12):908-11. doi: 10.3760/cma.j.issn.1007-3418.2011.12.007. Chinese. PubMed PMID: 22525503. Zheng X, Li W, Lan Z, Yang X, Li L, Yuan Y, Xia Z, Chen X, Zhang X, Yu Y. Antitumour effects of tetrazanbigen against human hepatocellular carcinoma QGY-7701 through inducing lipid accumulation in vitro and in vivo. J Pharm Pharmacol. 2015 Nov;67(11):1593-602. doi: 10.1111/jphp.12467. Epub 2015 Aug 5. PubMed PMID: 26245909. Yuan Y, Li W, Li L, Yang X, Gu R, Liu H, Huang K, Yu Y. Effects of tetrazanbigen on the protein expression in human hepatocellular carcinoma cell line QGY-7701. J Huazhong Univ Sci Technolog Med Sci. 2009 Jun;29(3):304-8. doi: 10.1007/s11596-009-0308-9. Epub 2009 Jun 10. PubMed PMID: 19513611. Yuan YH, Li W, Yang XL, Li LJ, Gu R, Tang WX, Yu Y. [Changes of protein expressions in human hepatocellular carcinoma cell line QGY-7701 induced by tetrazanbigen]. Zhonghua Gan Zang Bing Za Zhi. 2008 Jun;16(6):463-4. Chinese. PubMed PMID: 18579001.